We are on a mission to improve the well-being of people and planet. We believe that the future of hemp is unlimited. Through innovative and responsible application of science, we strive to enhance the prosperity and health of our employees, customers, and communities. We are committed to pioneering the CBD Evolution as the leading producer of quality hemp CBD products.
MCIG operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.
MCIG’ Pharmaceutical Division is developing synthetically-formulated cannabidiol-based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions.
MCIG’ Consumer Products Division delivers botanical-based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider’s offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician’s recommendations.
mCig has been featured in over 1000 articles by various print and online media sources.
mCig Inc. Announces Strategic Shift to Fully Focus on CBD Consumer Products Division and Healthcare DivisionDecember 12, 2019
JACKSONVILLE, FL – (NewMediaWire) – December 12, 2019 – mCig, Inc. (OTCQB:MCIG), a vertically integrated company focused on the deve...
MCIG Inc. Updates Shareholders on CBD-Based StrategyNovember 25, 2019
JACKSONVILLE, FL – (NewMediaWire) – November 25, 2019 – mCig, Inc. (OTCQB: MCIG), a company focusing on the marketing, sale, and dis...